Experienced Business Development and Client Relations Executive With Proven Record of Leadership

AREAS OF EXPERTISE

Medical Food and Nutritional Products

Business Development

Electronic Prescribing

Administration and Compliance of Vaccine Regiments

Contract Manufacturing

Finance

Client Relationship Management

EXPERIENCE

xCell Strategic Consulting – Principal

Pharma Tech Industries – Vice President of Strategic Sales

Sanofi – Director, Global Contract Manufacturing Business Development

InstantDx – Senior Vice President of Strategic Accounts

Schering-Plough Corp. – Senior Vice President, Business Development and Administration, MedAdvisor
– Executive in Residence, National Genetics Institute
– Vice President, Warrick Pharmaceuticals
– Director, Worldwide Contract Manufacturing
– Finance Director

ASSOCIATIONS

Council for Responsible Nutrition

Advisory Board, SSA Capital Company

EDUCATION

MBA, Rutgers University Business School

BA, Economics and Business, Rutgers University

 

 

Richard M. Loughlin, Principal

Rich is a pharmaceutical, consumer products and healthcare executive and has extensive business development, customer relationship management and finance experience with FDA-regulated corporations. He is seasoned in start-ups, transformations and carve-outs for worldwide Fortune 500 and privately-held companies.

Highlights:

  • Negotiated agreements and identified new accounts that delivered a total contract value of over $100M and maintained a 100% account retention rate for a privately owned CMO of Rx, nutritional, toiletry, medical devices and consumer disposable products. Identified the first medical food and nutritional products projects in the company resulting in multi-year supply agreements.
  • Launched a U.S.-based drug product contract manufacturing business resulting in over $100M in annual revenue for a multi-national pharmaceutical company.
  • Spearheaded the strategy and product development of electronically transmitted prescriptions for the first electronic prescribing company in the U.S. Identified early adopters and recruited physicians and hospitals to participate in the project.
  • Repositioned a subsidiary of a multi-national pharmaceutical company to address concerns regarding confidentiality of patient medical information. Achieved enhanced patient medication compliance by more than 30%.